OSR Holdings, Inc. has appointed Dr. Andreas Niethammer as the Chief Medical Officer of Vaximm AG, a subsidiary focused on developing innovative oral immunotherapies for cancer. This announcement, made on July 15, 2025, underscores OSR Holdings’ commitment to enhancing healthcare outcomes through advanced biomedical solutions.
Based in Basel, Switzerland, and Seoul, South Korea, OSR Holdings is dedicated to improving the quality of life for patients and their families. Dr. Niethammer brings over two decades of expertise in oncology, particularly in cancer immunotherapy, clinical development, and translational medicine. His previous leadership roles at prominent biopharmaceutical companies include Fate Therapeutics, NantKwest (now Immunity Bio), and Pfizer.
Under Dr. Niethammer’s leadership, Vaximm has successfully progressed its lead candidate, VXM01, into first-in-human clinical trials targeting pancreatic cancer and glioblastoma. He co-founded Vaximm to advance and commercialize therapeutic candidates based on his original research on oral T-cell vaccination conducted while at the Scripps Research Institute.
Dr. Niethammer’s Vision for Vaximm
Dr. Niethammer expressed enthusiasm about rejoining Vaximm, stating, “I am honored to rejoin Vaximm at this exciting moment in its evolution. With OSR Holdings’ support and resources, we are uniquely positioned to accelerate the development of powerful oral immunotherapies with the potential to improve outcomes for patients with difficult-to-treat cancers, as well as other diseases with high unmet needs.”
Dr. Constance Höfer, Chief Science Officer of OSR Holdings, commented on Dr. Niethammer’s appointment, noting, “We are thrilled to welcome Dr. Niethammer back to Vaximm as CMO leading Vaximm’s clinical strategy. His unique understanding of Vaximm’s foundational scientific concepts, combined with his deep global clinical development experience, perfectly place him to both continue the clinical advancement of the lead candidate VXM01 and drive platform and pipeline expansion in oncology as well as other disease areas.”
About Vaximm and OSR Holdings
Vaximm, a wholly owned subsidiary of OSR Holdings, is a Swiss-German biotech company that focuses on developing oral T-cell immunotherapies for cancer. Its proprietary platform aims to activate targeted cytotoxic T-cell responses through oral administration. Vaximm’s lead program, VXM01, has completed Phase I/II clinical trials in pancreatic cancer and glioblastoma, demonstrating promising potential in oncology.
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company devoted to advancing biomedical innovation to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. The company’s vision is to acquire and operate a portfolio of innovative healthcare firms, enhancing patient care through cutting-edge research and development.
